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Multiple sclerosisAlemtuzumab is a monoclonal antibody against the CD52 antigen present at high levels on the surface of lym-
phocytes. While treatment of multiple sclerosis patients with alemtuzumab results in marked depletion of
lymphocytes from the circulation, it has not been associated with a high incidence of serious infections. In
a human CD52 transgenic mouse, alemtuzumab treatment showed minimal impact on the number and func-
tion of innate immune cells. A transient decrease in primary adaptive immune responses was observed
post-alemtuzumab but there was little effect on memory responses. These results potentially help explain
the level of immunocompetence observed in alemtuzumab-treated MS patients.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Alemtuzumab is a humanized monoclonal antibody that speciﬁcally
binds human CD52 (huCD52), a 12 amino acid GPI-anchored protein
(Hale et al., 1990; Hale, 2001). CD52 is expressed at high levels on the
surface of T and B lymphocytes and at lower levels on natural killer
(NK) cells, monocytes, and macrophages (Hale et al., 1990; Rao et al.,
2012). There is little or no CD52 on neutrophils, plasma cells, or bone
marrow stem cells (Hale et al., 1990; Gilleece and Dexter, 1993).
While the exact function of CD52 is currently unknown, reports have
suggested that CD52 may play a role in cell–cell interactions as well as
T cell migration or co-stimulation (Rowan et al., 1995; Masuyama et
al., 1999; Watanabe et al., 2006).
Clinical trials have recently been completed comparing alemtuzumab
to interferonβ-1a (IFNβ-1a) therapy in treatment naive relapsing/
remitting MS (RRMS) patients (CAMMS223, CARE-MS I) and in
RRMS patients who experienced a relapse while on prior therapy
(CARE-MS II). In these randomized, rater-blinded trials, alemtuzumab
was administered intravenously at 12 or 24 mg/day for 5 consecutive
days at the start of the study and for 3 days one year later. IFNβ-1a
(44 μg) was administered subcutaneously 3 times per week for the
duration of the study. Patients in CAMMS223 may have received an
optional third course of treatment at the investigator's discretion
24 month after their ﬁrst dose of alemtuzumab. Using the co-primary+1 508 271 4694.
Turner).
.V. Open access under CC BY-NC-ND endpoints of relapse rate and progression of disability, alemtuzumab
showed overall greater clinical efﬁcacy than IFNβ-1a (Coles et al.,
2008; Cohen et al., 2012; Coles et al., 2012a, 2012b). In addition, long
term follow-up of patients from the Phase II study (CAMMS223) sug-
gested that alemtuzumab provides a long-lasting clinical beneﬁt as it
lowered the risk of sustained accumulation of disability by 72% and
the rate of relapse by 69% compared to IFNβ-1a out to four years after
the last alemtuzumab treatment (Coles et al., 2012a).
The mechanism by which alemtuzumab exerts its therapeutic effect
in MS is not fully understood but may involve rebalancing of the im-
mune system through the depletion and repopulation of lymphocytes.
The administration of alemtuzumab results in rapid depletion of
lymphocytes from the circulation which may reduce the inﬂammatory
processes associated with MS. This is followed by a prolonged period
of lymphocyte repopulationwith B cells returning to baseline levelswith-
in 6 months and T cell counts rising more slowly, generally approaching
the lower limit of normal levels by 12 months post-treatment. Research
ﬁndings suggest that alemtuzumab alters the number, proportions and
properties of lymphocyte subsets during repopulation which may con-
tribute to its long term treatment effect (Cox et al., 2005; Jones et al.,
2010; Thompson et al., 2010). Multiple sclerosis patients treated with
alemtuzumab also display an increase in the frequency of secondary au-
toimmune conditions, primarily thyroid disorders and, less frequently,
immune thrombocytopenia (Cohen et al., 2012; Coles et al., 2012b). The
factors responsible for development of secondary autoimmunity in a
subset of patients are poorly understood and remain an active area of
investigation (Jones et al., 2009; Cossburn et al., 2011; Costelloe et al.,
2012).
An understanding of the relationship between the observed
lymphopenia, immune status, and protective immunity post-
alemtuzumab has also been lacking. In spite of the markedlicense.
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served after treatment, MS patients did not experience a high inci-
dence of serious infections (Coles et al., 2008; Cohen et al., 2012; Coles
et al., 2012a, 2012b). An increase in the overall incidence of infection
was observed in alemtuzumab-treated vs. IFNβ-1a-treated patients
(66–77% vs. 45–66%, respectively, across the Phase II and III trials)
but most were mild to moderate in severity and responded to con-
ventional treatment. The most common infections were upper respi-
ratory and urinary tract infections. The highest incidence of infection
occurred during the ﬁrst month following alemtuzumab treatment.
Acyclovir prophylaxis was implemented during that period to decrease
the incidence of herpes infection. Importantly, infection rates did not
increase after the second or, in some cases, third course of alemtuzumab
(Coles et al., 2008; Cohen et al., 2012; Coles et al., 2012a, 2012b).
In order to better understand the impact of alemtuzumab on the im-
mune status of the host beyond the phenotypic analysis conducted on pe-
ripheral blood fromMS patients, a huCD52 transgenic mouse model was
used to systematically characterize the effect of treatment on the func-
tionality of various immune system components. The results showed a
minimal impact of alemtuzumab treatment on the number and function
of innate immune cells. There was also little effect of alemtuzumab on
memory B and T cell responses while primary immune responses were
transiently decreased. Overall, the level of preserved immunocompetence
measured post-alemtuzumabmay help explainwhy therewas not a high
incidence of serious infections in alemtuzumab-treated MS patients.
2. Materials and methods
2.1. Mice and tissue collection
HumanCD52 transgenicmicewere generated andmaintained as de-
scribed previously (Hu et al., 2009). Brieﬂy, huCD52 transgenic mice
were created by microinjecting CD1 embryonic mouse stem cells with
a bacmid construct containing ~145 kilobases of genomic DNA from
human chromosome 1 and the entire huCD52 gene and promoter re-
gion. All experimental protocols were approved by the Genzyme Insti-
tutional Animal Care and Use Committee and studies were conducted
in Genzyme's Association for Assessment andAccreditation of Laborato-
ry Animal Care accredited facility. All studies were performed using a
single intravenous injection of alemtuzumab or Remicade™ (Hanna
Pharmaceutical, Willmington, DE) at 1 mg/kg or an equivalent volume
of vehicle prior to the initiation of the experimental procedures.
2.2. Quantitation of cellular populations by ﬂow cytometry
Quantitation of immune cell populations in the spleen, thymus, and
pooled lymph nodes (including inguinal, axillary, brachial, cervical, and
mesenteric nodes) was performed by producing single cell suspensions
from these organs. Bone marrow cells were obtained by ﬂushing the
tibiae and femurs with HBSS. The total number of immune cells in
each organ was measured using a Coulter Counter (Beckman Coulter,
Indianapolis, IN). Polychromatic ﬂow cytometry was performed to
quantify various cell types following alemtuzumab administration.
Staining of immune cells was performed by incubating 1 × 106 cells
with ﬂuorescently-labeled antibodies for mouse cell surface markers
including CD4 (RM4-5), CD8 (53–6.7) CD44 (1M7), CD62L (Mel-14),
CD25 (PC61.5), FR4 (12A5), B220 (RA3-6B2), CD93 (AA4.1), NK1.1
(PK136), F4/80 (8M8), CD11b (M1/70), and GR-1 (RB6.8C5) purchased
from Ebioscience (San Diego, CA) or BD Bioscience (San Jose, CA). Vβ
analysis was performed by staining splenocytes from vehicle- or
alemtuzumab-treated animals with a panel of ﬂuorescein-labeled
anti-Vβ speciﬁc antibodies as described by the manufacturer (BD
Bioscience, San Jose, CA). Peripheral blood was evaluated by staining
50 μl of whole bloodwith the indicated antibodies followed by removal
of contaminating red blood cells with FACS lysis buffer (BD Bioscience,
San Jose, CA) as described by themanufacturer. Fluorescence intensitieswere determined using an LSR-II ﬂow cytometer (BD Bioscience, San
Jose, CA) and data analysis was performed using Flowjo software
(Treestar Inc., Ashland, OR).
Quantiﬁcation of absolute numbers of speciﬁc cell populations
in the spleen, lymph nodes, thymus, and bone marrow was deter-
mined bymultiplying the percentage of the FACS-identiﬁed cellular
population by the total number of cells present in each organ. Num-
bers of speciﬁc cell populations per microliter of peripheral blood
were quantiﬁed using Countbright Absolute Counting Beads
(Invitrogen Life Technologies, Grand Island, NY) as described by
the manufacturer (# cells/μl = number of cells counted/number
of beads counted × number of beads added). Absolute numbers of
cell populations in the peripheral blood of each animal was calcu-
lated by multiplying the number of cells/μl for each speciﬁc popula-
tion by the estimated volume of blood (3000 μl) in these animals
(40 g average body weight/mouse). Percent control for all tissues
was calculated by dividing the number of total cells for each population
by the mean total number of the same cellular population from the
vehicle-treated control group [total cells in test animal / mean of total
cells in control group × 100].
2.3. Chromium release assay
NK cell function was evaluated by performing a standard chro-
mium release assay on puriﬁed NK cells. Brieﬂy, NK cells from the
spleens of alemtuzumab- or vehicle-treated animals were isolated
by negative selection using antibody-coated magnetic beads as
described by the manufacturer (Miltenyi Biotec, Auburn, CA). NK
cells were cultured with 51chromium-labeled YAK-1 target cells at
various effector:target ratios. After 5 h of incubation, the amount
of 51chromium released in the supernatant was measured in a
MicroBeta Trilux Scintillation Counter (Wallac, Gaithersburg, MD).
The amount of 51chromium spontaneously released was obtained by
incubating target cells alone in medium. Spontaneous release was
typically below 20%. The total amount of 51chromium incorporated by
the target cells was determined by adding 1% Triton X-100 in distilled
water, and the percent speciﬁc lysis was calculated as follows: [(sample
cpm − spontaneous cpm) / (total cpm − spontaneous cpm)] × 100.
2.4. Antibody responses
T-independent antibody responses were evaluated by immuniz-
ing huCD52 transgenic mice with 100 μg of DNP-conjugated Ficoll
(Biosearch Technologies, Novato, CA) intraperitoneally either 21 or
3 days after alemtuzumab treatment. Five days later, serum was col-
lected and anti-DNP titers determined by an anti-DNP IgM-speciﬁc
ELISA. Brieﬂy, DNP-KLH or KLH alone were coated in phosphate-
buffered saline (PBS) on high protein binding ELISA plates. Anti-
bodies present in serially diluted serum samples were detected
with an HRP-labeled anti-IgM speciﬁc secondary antibody (Jackson
Immunoresearch Laboratories Inc., West Grove, PA) followed by
incubation with TMB substrate.
Similarly, T-dependent antibody responses were evaluated follow-
ing subcutaneous immunization with 100 μg of DNP-conjugated
chicken gamma globulin (CGG) (Biosearch Technologies, Novato, CA)
emulsiﬁed in Complete Freund's Adjuvant (Chondrex Inc., Redmond,
WA) either 21 or 3 days following alemtuzumab treatment. Fourteen
days later, serumsampleswere collected and evaluated for DNP reactiv-
ity using an ELISA assay similar to that described above with a second-
ary antibody speciﬁc for IgG antibodies (Jackson Immunoresearch
Laboratories Inc., West Grove, PA).
2.5. Peritonitis assay
Peritonitis was induced by injecting thioglycolate intraperito-
neally (Becton Dickenson, Franklin Lakes, NJ) three days following
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ﬂushing the peritoneal cavity with PBS 24 or 48 h after thioglycolate in-
jection. Samples of exudate cells from individual micewere analyzed by
ﬂow cytometry (see above) and CD11b positive cells were negatively
puriﬁed from the remaining population by MACS isolation according
to the manufacturer's recommendations (Miltenyi Biotec, Auburn,
CA). CD11b-enriched cells were then tested for phagocytic activity
using a colorimetric assay (Cell Biolabs Inc., San Diego, CA) and for
cytokine production. CD11b-enriched exudate cells (5 × 105) were
cultured overnight in complete RPMI medium and stimulated with
10 μg/ml of LPS for an additional 24 h. The levels of cytokines released
in the culture medium were then quantiﬁed by cytometric bead array
(CBA) as described by the manufacturer (BD Bioscience, San Jose, CA).
2.6. Functional T cell assay
Functional activity of T cells was evaluated three days after
alemtuzumab treatment. Cellular proliferation was tested by culturing
splenocytes in the presence of plate-bound anti-CD3 (3 μg/ml) for
72 h followed by an additional 24 h with 1 μCi of 3H-thymidine. In par-
allel cultures, supernatant was collected after 24 h of incubation and
evaluated for cytokine levels using a mouse Th1/Th2 cytometric bead
array as described by the manufacturer (BD Bioscience, San Jose, CA).
Anti-adenovirus T cell responses were evaluated by immunizing
huCD52 transgenic mice subcutaneously with 1 × 109 infectious units
of recombinant adenovirus serotype 2 (Ad2). Immunizations were
performed as described in the Results section. Anti-Ad2 speciﬁc T cells
were identiﬁed by IFNγ ELISPOT assay. Brieﬂy, multiscreen-IP plates
were coated with 5 μg/ml of rat anti-muIFNγ antibody (RMMG-1,
Biosource, Grand Island, NY) for 1 h at 37 °C. The plate was blocked
for 1 h with complete RPMI at humidiﬁed 37 °C. Splenocytes were
added in the presence or absence of 10 μg/ml of heat-killed Ad2 virus.
Twenty-four hours later, splenocytes were removed and bound IFNγ
was detected with 2 μg/ml of biotinylated rat anti-muIFNγ antibody
(XMG1.2, BD Bioscience, San Jose, CA) diluted in PBS. Two hours later,
excess secondary antibody was removed and bound antibody was
detected with a 1:800 dilution of streptavidin-AP in PBS and developed
with BCIP reagent (Kirkegaard & Perry Laboratories, Gaithersburg, ML).
2.7. Statistical analysis
Analysis was performed onGraphPad Prism 5.0 (GraphPad Software
Inc., La Jolla, CA). Data are presented as the mean +/− standard error;
p values were determined by Student's t test.
3. Results
3.1. Differential depletion of immune cells by alemtuzumab in human
CD52 transgenic mice
Alemtuzumab is a humanized monoclonal antibody that speciﬁcally
recognizes human CD52 (huCD52) and does not cross-react with
murine CD52 due to sequence differences between the human and
mouse proteins. Therefore, a huCD52 transgenic mouse model was
used to investigate the impact of alemtuzumab treatment on immune
function. As described previously, the tissue distribution and levels of
huCD52 expression on various immune cell populations in these mice
are similar to those observed in humans (Hu et al., 2009; Rao et al.,
2012) and treatment with alemtuzumab results in a similar pattern of
immune cell depletion (Hu et al., 2009). In this study, the nature and
functionality of immune cell subsets remaining post-alemtuzumab
treatment were investigated in greater detail. First, the distribution of
major immune cell populations was evaluated in mice treated with a
single dose of alemtuzumab approximating the total dose administered
toMS patients (1 mg/kg). Analysis conducted at 3 days post-treatment,
when maximal lymphocyte depletion occurs (supplemental Fig. 1),showed a dramatic reduction in the number of immune cells in the
blood with a lesser impact in lymphoid organs. Importantly, only a
small percentage of total cells are actually found in the blood and signif-
icant numbers of immune cells were still present in the bone marrow,
lymph nodes, thymus and spleen of animals post-alemtuzumab
(Fig. 1a). These results suggest that measurement of circulating blood
cell counts alone does not accurately reﬂect the totality of the immune
system and may overestimate the degree of immune cell depletion
post-alemtuzumab.
Examination of the immune cell populations remaining in the
spleen 3 days after alemtuzumab treatment showed that T and B lym-
phocytes, which express high levels of CD52 (Hu et al., 2009), were
most susceptible to depletion while innate immune cells including
natural killer (NK) cells, macrophages and polymorphonuclear leuko-
cytes (PMNs), which express little CD52 (Hu et al., 2009),were relative-
ly unaffected or even proportionately increased (Fig. 1b). Similarly, in
the blood, T and B lymphocytes were strongly depleted (Fig. 1c) while
innate immune cells underwent a signiﬁcantly lower level of depletion
with a rapid recovery to baseline (Fig. 1d). Lymphocytes underwent a
gradual repopulation over 100 days with B lymphocytes recovering
faster than T lymphocytes (Fig. 1c). This pattern of peripheral blood
lymphocyte depletion and repopulation with relative sparing of innate
immune cells mirrors that observed in MS patients treated with
alemtuzumab (Coles et al., 2010).
3.2. Minimal impact of alemtuzumab treatment on the function of innate
immune cells
The number of innate immune cells did not appear to be greatly
affected by alemtuzumab treatment and we next sought to assess
their functionality. NK cells isolated from spleens at 3 days post-
alemtuzumab treatment were tested for their ability to lyse target
cells in a standard chromium release assay. As illustrated in Fig. 2a,
the lytic activity of NK cells from vehicle- and alemtuzumab-treated
mice was comparable at all effector:target (E:T) ratios tested. These re-
sults indicate that after alemtuzumab treatment, remaining NK cells are
functionally intact.
The activity of macrophages and polymorphonuclear leukocytes
(PMNs) was evaluated in vivo using a peritonitis model of inﬂamma-
tion. Human CD52 transgenic mice were treated with vehicle or
alemtuzumab and were injected intraperitoneally 3 days later with
thioglycolate to induce local inﬂammation. The ability of innate im-
mune cells to respond to this inﬂammation andmigrate into the perito-
neal cavity was assessed 24 and 48 h later by measuring the total
number of cells recovered by peritoneal lavage and by characterizing
the nature of the cells present in the peritoneal exudate by polychro-
matic ﬂow cytometry. As demonstrated in Fig. 2b, animals that were
not injected with thioglycolate displayed a relatively small number of
resident cells in the peritoneal cavity. Animals receiving thioglycolate
showed an approximately 3 fold increase in the number of cells isolated
from the peritoneal cavity at 24 and 48 h. Importantly, there was no
statistically signiﬁcant difference in the number of inﬁltrating cells in an-
imals treatedwith vehicle or alemtuzumabdemonstrating an equivalent
recruitment of immune cells at the site of inﬂammation. In addition, the
composition of the cellular exudate was comparable in both groups as
determined by staining for B cells, eosinophils, mast cells, macrophages,
monocytes and PMNs at the 48-hour time point (Fig. 2b). These results
indicate that alemtuzumab treatment has little impact on themagnitude
and quality of the inﬂammatory response in this model.
The functional activity of themacrophages recruited into the perito-
neal cavity was next assessed bymeasuring their ability to phagocytose
particles and secrete cytokines in response to stimulationwith bacterial
lipopolysaccharide (LPS). As illustrated in Fig. 2c, CD11b+macrophages
enriched from the peritoneal exudate of vehicle-treated (purity
91.6 +/− 2.5%) and alemtuzumab-treated (purity 94.2 +/− 2.1%)
animals showed equivalent levels of phagocytosis of labeled particles
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Fig. 1. Alemtuzumab-mediated depletion and repopulation of immune cells in huCD52 transgenic mice. Immune cell depletion was evaluated in huCD52 transgenic mice three days fol-
lowing intravenous treatment with vehicle or alemtuzumab (Alem). (A) Total numbers of immune cells were obtained from a single cell suspension of the primary and secondary lym-
phoid organs indicated. (B) Cellular subsets were quantiﬁed by polychromatic ﬂow cytometry in the spleen three days following treatment with vehicle or alemtuzumab. (T cells: CD4+
and CD8+; B cells: B220+; NK cells: NK1.1+; PMN: Gr-1+) *p b 0.01; #p b 0.05 by Student's t test. Repopulation of lymphocyte (C) or innate immune cell subsets (D) following
alemtuzumab treatment of huCD52 transgenic mice: absolute numbers of the indicated cell populations were periodically quantiﬁed in the peripheral blood after alemtuzumab treat-
ment. Error bars indicate the standard error of the mean of 4 to 5 animals/group. In panels (C) and (D), statistically signiﬁcant differences compared to control were observed for
CD4+ and CD8+ T cells from day 3 to day 56, for B cells from day 3 to day 40, and day 3 for NK cells. BM: bonemarrow, LN: lymph nodes, NK cells: natural killer cells, PMN: polymorpho-
nuclear leukocytes, Macs: macrophages. Experiments were performed three times with similar results.
Fig. 2. Characterization of innate immune cell function following alemtuzumab treatment. (A) The lytic activity of NK cells isolated from the splenocytes of huCD52 transgenic mice
three days following alemtuzumab (Alem) treatment was tested at various effector:target (E:T) ratios in a 51Cr release assay. (B) Enumeration of peritoneal exudate cells following
alemtuzumab treatment and thioglycolate (thio) injection. HuCD52 transgenic mice were treated with alemtuzumab and 3 days later injected intraperitoneally with thioglycolate.
The total numbers of exudate cells (left) and speciﬁc cellular subsets (right) were quantiﬁed either 24 or 48 h after thioglycolate injection (gray-untreated, black-vehicle control,
white-alemtuzumab). Eos: eosinophils, Mast: mast cells, Mac: macrophages, Mono: monocytes, PMN: polymorphonuclear leukocytes. (C) Phagocytic activity of enriched CD11b
exudate cells was evaluated at 24 and 48 h post-injection of thioglycolate. (D) Release of IL-6, IL-12 (p40) and MCP-1 by CD11b-enriched exudate cells was evaluated following
24 h in vitro stimulation with LPS. Also measured but not shown: G-CSF, GM-CSF, IFN-γ, MIP1α and RANTES. No statistically signiﬁcant differences were observed between
alemtuzumab and vehicle control groups by Student's t test for any of the read-outs. Error bars indicate the standard error of the mean of 4 to 5 animals/group. Studies were
performed twice with similar results.
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Fig. 3. Characterization of B cell responses following alemtuzumab therapy. (A) Mature
(B220+, CD93lo) and immature B cell (B220+, CD93hi) subsets were quantiﬁed in the
spleens of huCD52 transgenic mice three days after alemtuzumab treatment. (B, C) Eval-
uation of T-independent and T-dependent antibody responses. Human CD52 transgenic
mice were treated with vehicle (circle) or alemtuzumab at 21 (squares) or 3 (triangles)
days prior to immunizationwith DNP-Ficoll (B) or DNP-CGG (C). Anti-DNP antibody titers
were then evaluated by ELISA either 5 or 14 days after immunization, respectively.
T-independent antibody responses were performed by evaluating the binding of IgM
anti-DNP antibodies to DNP conjugated to KLH (black symbols) or KLH alone (gray sym-
bols). T-dependent antibody responses were quantiﬁed by an IgG anti-DNP speciﬁc ELISA
against the same antigens. Error bars indicate the standard error of the mean of 3–5
animals/group. *p b 0.05 by Student's t test. Studies were performed twice with similar
results.
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leased similar levels of proinﬂammatory cytokines when stimulated
with LPS (Fig. 2d). Overall, these data indicate that the ability of innate
immune cells to respond to inﬂammation in vivo was not signiﬁcantly
impacted by treatment with alemtuzumab.
3.3. Modest impact of alemtuzumab treatment on primary B cell responses
As shown in Fig. 1c and as observed inMS patients, administration of
alemtuzumab results in amarked decrease in the number of circulating B
lymphocytes suggesting that the development of antibody responses
may be reduced after treatment. However, as described above, even
when most lymphocytes are depleted from the circulation, signiﬁcant
numbers of B and T cells are still present in lymphoid organs and are
presumably still available to mount an immune response (Fig. 3a, Hu et
al., 2009). The ability of alemtuzumab-treated huCD52 transgenic mice
to develop antibodies in response to immunization with model
T-dependent and T-independent antigens was therefore investigated.
Animals were immunized with DNP-conjugated Ficoll (DNP-Ficoll;
T-independent) or DNP-conjugated chicken gammaglobulin (DNP-CGG;
T-dependent) either 3 days (maximal lymphocyte depletion) or 21 days
after alemtuzumab treatment. Levels of DNP-speciﬁc IgM antibodies in
the serum of animals immunized with the T-independent DNP-Ficoll
antigen were measured by ELISA 5 days after immunization. As demon-
strated in Fig. 3b, mice treated with alemtuzumab developed IgM
antibody responses similar to those of vehicle-treated animals when
challenged 3 or 21 days post-alemtuzumab. Levels of DNP-speciﬁc IgG
antibodies were also measured by ELISA 14 days after immunization
with the T-dependent DNP-CGG antigen. In this instance, a decrease in
the level of serum antibodies to DNP was observed when immunization
occurred 3 days after alemtuzumab treatment but antibody responses
were back to the levels obtained in vehicle control animals by 21 days
post-alemtuzumab (Fig. 3c). Overall, these results suggest a modest
impact of alemtuzumab treatment on B cell responses, as illustrated by
no measurable effect of alemtuzumab on the development of a de novo
antibody response to a T-independent antigen but a decrease in
T-dependent antibody at the nadir of lymphocyte depletion.
3.4. Preservation of function and diversity in residual T cells post-
alemtuzumab
We next investigated whether T cells remaining after alemtuzumab
treatment still exhibited normal functional activity. In these studies,
huCD52 transgenic mice were treated with alemtuzumab or vehicle
and three days later splenocytes were evaluated for their ability to
proliferate and produce cytokines in response to polyclonal stimulation
with plate-bound anti-CD3. The actual number of T cells present in the
splenocyte cultures was determined by ﬂow cytometry and the results
are expressed on a per cell basis. As shown in Fig. 4a and b, T cells from
alemtuzumab- or vehicle-treated mice proliferated at a similar rate and
released comparable levels of Th1, Th2, and Th17 type cytokines indi-
cating retention of function in residual T cells post-alemtuzumab.
In addition, an analysis of T cell receptorVβ expressionwas conducted
to determine whether particular Vβ families might be more susceptible
to alemtuzumab-mediated depletion thereby potentially causing a
skewing in the T cell repertoire. Using a ﬂow cytometry-based analysis
of Vβ expression by splenic CD4 andCD8 T cells, no signiﬁcant differences
were observed in the distribution of Vβ families in alemtuzumab- and
vehicle-treated mice for either T cell subset (Fig. 4c, d) except for varia-
tions in some minor populations (e.g. Vβ2, Vβ3 and Vβ17a in CD4 T
cells). Similarly, Vβ analysis of central memory, effector memory,
naïve and T regulatory cells failed to show any overall differences
in diversity following treatment with alemtuzumab vs. vehicle
(data not shown). Taken together, these data indicate that T cells
present post-alemtuzumab treatment retained normal functionalactivity and that alemtuzumab treatment did not introduce a bias
in the diversity of the T cell receptor repertoire.
3.5. Adenovirus-speciﬁc T cell responses in alemtuzumab-treated mice
The previous data indicate that, while alemtuzumab treatment
reduced the overall number of T lymphocytes, the cells that remained
were capable of responding functionally and the overall spectrum of T
cell receptor diversity was maintained. This suggests that a certain
level of immune reactivity in response to immunization or infection
may also be maintained post-alemtuzumab. Further analysis of the
T cell populations present in the spleen after alemtuzumab treatment
showed that naïve CD4+ and CD8+ T cells were the most susceptible
to depletion while memory T cells (central and effector memory), as
well T regulatory cells, were depleted to a lesser extent (Fig. 5a, b)
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Fig. 4. T cell function and repertoire are unchanged following alemtuzumab treatment. T cell function was assessed in huCD52 transgenic mice three days following alemtuzumab
(white bars) or vehicle (black bars) treatment. Splenic cultures were evaluated for proliferative capacity (A) and cytokine production (B) following anti-CD3 stimulation in vitro.
Overall responses were normalized to the total number of T cells within the assay following ﬂow cytometric evaluation. CD4 (C) and CD8 (D) T cell repertoire diversity was
evaluated for Vβ expression by ﬂow cytometry three days after alemtuzumab treatment. Error bars indicate the SEM of 5 animals/group. *p b 0.05 by Student's t test. Studies
were performed twice with similar results.
34 M.J. Turner et al. / Journal of Neuroimmunology 261 (2013) 29–36suggesting that memory T cell responses may be preserved. This possi-
bility was investigated in huCD52 transgenic mice challenged with an
adenovirus vector (Ad2).
To study the effect of alemtuzumab on primary T cell responses,
huCD52 transgenic mice were immunized with Ad2 either 7, 21 or
35 days following treatment with alemtuzumab or vehicle as a control.
The frequency of Ad2-speciﬁc T cells was measured by IFNγ ELISPOT
14 days after immunization as described in Materials and methods.
As demonstrated in Fig. 6a, the magnitude of the Ad2-speciﬁc T cell
response was reduced at 7 and 21 days following alemtuzumabFig. 5. Alemtuzumab-mediated depletion of T lymphocytes. Splenic CD4 (A) and CD8 (B) T
ment with alemtuzumab. Cellular subsets were identiﬁed by multiparameter ﬂow cytomet
group. *p b 0.01; #p b 0.05 by Student's t test. CM: central memory (CD62Lhi, CD44hi), EM
FR4hi). Studies were performed three times with similar results.treatment and returned to control levels by 35 days. Interestingly,
the recovery in T cell responses was observed well before the numbers
of circulating T cells had returned to baseline (Fig. 1a). These data indi-
cate that alemtuzumab treatment resulted in a transient reduction of
the primary T cell response to Ad2.
As described above, memory T cells appeared to be less susceptible to
alemtuzumab-mediated depletion compared to naïve T cells. We there-
fore evaluated whether this observation might translate into the preser-
vation of memory immune responses post-alemtuzumab. Human CD52
transgenic mice were immunized with Ad2 and allowed to develop acell subsets were quantiﬁed in huCD52 transgenic animals three days following treat-
ry and compared to vehicle-treated animals. Error bars indicate the SEM of 5 animals/
: effector memory (CD62Llo, CD44hi), Naïve: (CD62Lhi, CD44lo), Treg: (CD4+, CD25hi,
35M.J. Turner et al. / Journal of Neuroimmunology 261 (2013) 29–36memory response over 30 days. The animals were then treated with
alemtuzumab or vehicle and were rechallenged with Ad2 vector 3 days
later. The frequency of Ad2-speciﬁc T cells was again measured by IFNγ
ELISPOT but this time at 7 days post-challenge to capture the more
rapid memory response. Control groups included animals that did not
receive any immunization with Ad2 as well as animals that did not
receive the second rechallenge. As shown in Fig. 6b, animals immunized
a second time with Ad2 developed a response signiﬁcantly greater than
that obtained with a single immunization, demonstrating the increased
potency of the recall response generated. Importantly, the magnitude
of the Ad2-speciﬁc memory T cell response was comparable in
alemtuzumab- and vehicle-treated animals suggesting that memory T
cell responses are relatively unaffected by alemtuzumab.
4. Discussion
Treatment of MS patients with 2 courses of alemtuzumab, at ini-
tiation of treatment and 1 year later, has shown superior efﬁcacy
compared to s.c. IFNβ administered 3 times weekly in Phase II and
III clinical trials (Coles et al., 2008; Cohen et al., 2012; Coles et al.,
2012a, 2012b). Administration of alemtuzumab gives rise to a ro-
bust depletion of CD52+ lymphocytes from the circulation and,
while B lymphocyte counts typically return to baseline within
6 months, T cell recovery is slower and generally reaches the lower
limit of normal by 11–12 months (Coles et al., 2012a). In spite of this
observed lymphopenia, only 3% of alemtuzumab-treated MS patients
in clinical trials developed serious infections. An increase in the overall
incidence of infection was observed in alemtuzumab-treated vs.
IFNβ-treated patients but the vast majority of infections were mild to
moderate in severity and responded to conventional treatment (Coles
et al., 2008; Cohen et al., 2012; Coles et al., 2012a, 2012b). These ﬁnd-
ings suggest that the perceived risk of infection suggested by low lym-
phocyte blood counts may not reﬂect the actual immune status of the
host. Results obtained in this study using huCD52 transgenic mice mir-
ror some of the observationsmade inMS patients and provide addition-
al information that may help explain the level of immune protection
observed in alemtuzumab-treated patients. First, analysis of lymphoid
tissues, which were not sampled in the human clinical trials, indicates
that the loss of immune cells from the circulation post-alemtuzumab
represents only a small percentage relative to the totality of the im-
mune system. This suggests that many immune cells are still present
in the remainder of the body and are available to participate in anFig. 6. Characterization of primary and memory T cell responses in alemtuzumab-treated hu
opment of Ad2-speciﬁc T cells following treatment with alemtuzumab (Alem) 7, 21, or 35 d
immunization, antigen-speciﬁc T cells were evaluated by IFNγ ELISPOT assay using heat-kil
icant differences were observed between animals treated with vehicle or alemtuzumab. (B)
virus and rechallenged with Ad2 three days after alemtuzumab treatment. Seven days fo
Ad2-speciﬁc T cells by IFNγ ELISPOT assay. Error bars are the SEM of 4–5 animals per group.
Ad2 immunizations in the presence of vehicle or alemtuzumab, or between animals recei
performed twice with similar results.immune response. In addition, very little depletion was observed
in the bone marrow and thymus, the primary lymphoid organs
that are essential to lymphocyte repopulation. The low degree of
alemtuzumab-mediated depletion in these organs may be explained
by the absence or minimal expression of CD52 by bone marrow stem
cells and early thymocyte populations and/or by reduced access of
the antibody to these sites (Hale et al., 1990; Gilleece and Dexter,
1993; Hu et al., 2009). Clark et al. have also recently reported that,
in alemtuzumab-treated cutaneous T cell lymphoma patients, the
paucity of neutrophil-mediated antibody-mediated cellular cytolysis
(ADCC) in the skin resulted in preservation of skin resident effector
memory T cells (Clark et al., 2012). A low abundance of effector
mechanisms in organs such as the thymus may also play a role in
lymphocyte preservation post-alemtuzumab.
Although the actual number of lymphocytes is reduced post-
alemtuzumab, functional analysis in mice indicated that the activity
of the remaining lymphocytes is unimpaired. Splenic T lymphocytes
from alemtuzumab-treated mice showed normal proliferation and
cytokine production in response to anti-CD3 stimulation (Fig. 4a,
b). In addition, Vβ analysis of T cell receptors from bulk CD4 and
CD8 T cells (Fig. 4c, d) as well as central memory, effector memory,
naïve and T regulatory cells (data not shown) indicated that T cell
receptor diversity was maintained post-alemtuzumab and that treat-
ment with the antibody did not introduce a bias toward any particular
Vβ family.
Another important ﬁnding is the limited impact of alemtuzumab
on the innate immune system. In both humans and huCD52 trans-
genic mice, innate immune cells including NK cells, macrophages
and PMNs express only low levels of CD52 and undergo limited
depletion with a rapid return to baseline (Fig. 1d; Coles et al.,
2010). In this study, the functionality of innate immune cells was
also shown to be preserved post-alemtuzumab. Natural killer cells
from alemtuzumab-treated mice showed normal cytolytic activity
ex vivo and normal innate immune responses to peritonitis were ob-
served in vivo. Equivalent numbers and types of cells migrated into
the peritoneal cavity of alemtuzumab-treated and control mice in
response to thioglycolate-induced inﬂammation and the macro-
phages recovered from the peritoneal cavity displayed normal
phagocytic and cytokine-producing abilities. These results suggest
that the innate immune system, which represents the ﬁrst line of
defense against infection, is minimally impacted by alemtuzumab
treatment.CD52 transgenic mice. (A) Human CD52 transgenic mice were evaluated for the devel-
ays prior to immunization with recombinant Ad2 or PBS. Fourteen days following the
led Ad2 vector. Error bars are the SEM of 4–5 animals per group. No statistically signif-
Ad2-speciﬁc memory T cell responses were evaluated in animals immunized with Ad2
llowing the second immunization, splenocytes were evaluated for the frequency of
No statistically signiﬁcant differences were observed between animals receiving single
ving secondary immunizations following vehicle or alemtuzumab. Experiments were
36 M.J. Turner et al. / Journal of Neuroimmunology 261 (2013) 29–36Assessment of speciﬁc acquired immune responses was also
conducted. In studies of B cell function, the antibody response to a
model T-independent antigen was not signiﬁcantly affected by
alemtuzumab treatment suggesting that remaining B lymphocytes
were sufﬁcient to mount a normal antibody response. By compari-
son, there was a transient decrease in the antibody response to a
model T-dependent antigen when immunization occurred soon
after alemtuzumab treatment (day 3) with a recovery to control
levels by day 21 post-alemtuzumab. An impact on primary T cell re-
sponses was also observed in mice immunized with adenovirus.
Compared to control, there was a decrease in the IFNγ ELISPOT T
cell response to Ad2 when immunization occurred 7–21 days
post-alemtuzumab, although the difference was not statistically dif-
ferent in this study (Fig. 6a). Importantly, the T cell response to ade-
novirus immunization returned to control levels by day 35
post-alemtuzumab, at a time when peripheral T lymphocyte counts
were still below normal (Fig. 1c). These results suggest that protec-
tive levels of T cell immunity against infection can still be present
in the face of lymphopenia. This may be due, at least in part, to the
recovery of sufﬁcient numbers of lymphocytes in the lymphoid or-
gans that can participate in the development of immune responses.
The animal data are also in agreement with the MS clinical data
showing that the highest incidence of infection occurs in the ﬁrst
month post-alemtuzumab treatment and declines thereafter even
though blood T cell counts remain below the normal range (Coles
et al., 2012a).
Interestingly, subset analysis of the T cell populations remaining
in huCD52 transgenic mice post-alemtuzumab indicated that T cells
with a central memory, effector memory and regulatory phenotype
were proportionately depleted to a lesser extent than naïve T cells
(Fig. 5a, b). A similar pattern has also been observed in the peripheral
blood of MS patients post-alemtuzumab (Cox et al., 2005). This
ﬁnding suggested that memory recall responses may be relatively
unaffected following alemtuzumab treatment. Testing of this possi-
bility in the huCD52 transgenic mouse indicated that there was in
fact little or no impact of alemtuzumab treatment on the memory
response to adenovirus (Fig. 6b). Animals immunized with adenovirus
30 days prior to alemtuzumab treatment developed T cell (Fig. 6b)
and antibody (not shown) responses comparable to those of control an-
imals when rechallenged with adenovirus. These results suggest that
memory responses developed as a result of prior infections or immuni-
zations may not be dramatically impacted by alemtuzumab treatment.
Overall, our results indicate that alemtuzumab treatment of
huCD52 transgenic mice within the dose range used in MS patients
allows for maintenance of a level of immune competence characterized
by largely unaffected innate immunity, functionality of remaining
lymphocytes, and a transient decrease in the ability to respond to
novel antigens with little impact on memory responses. These animal
data may help explain why alemtuzumab-treated MS patients have
not experienced a high incidence of serious infections.
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